What are clinical trails?
Participating in a clinical trial is not just contributing to research — it’s a proactive healthcare choice. Clinical trials offer access to advanced medical care, often including more frequent monitoring, extra diagnostic testing, and expert oversight from specialized healthcare teams. Participants may receive investigational treatments that have shown promising results and are not yet available to the general public. These therapies often represent the latest innovations in medicine, offering hope and potential benefits beyond current standard care.
In addition to the potential personal health benefits, participants are often compensated for their time and travel, making involvement more accessible. Most importantly, by joining a clinical trial, you’re playing a vital role in the advancement of science and helping shape the future of medicine — paving the way for better treatments for yourself and others.
Why participate in a clinical trial?
Care at No Cost
Our clinical trials provide qualifying participants with high-quality medical care at no charge. This includes regular health checkups, specialized testing, and ongoing monitoring — services that may otherwise be costly or difficult to access.
Access to Cutting-Edge Treatments
Participants may gain early access to innovative treatments and medications that are not yet widely available but have shown promising results in previous studies. These investigational therapies represent the forefront of medical advancement — and are offered at no cost to eligible participants.
Compensation and Support
In most studies, participants are compensated for their time, travel, and participation. While treatments are provided free of charge, this additional support helps offset the personal investment of being part of a trial.
Make a Meaningful Impact
By joining a clinical trial, you’re not only exploring a new care option for yourself — you’re helping advance medical research and contributing to discoveries that could improve or save lives in the future.
Gain Insight and Empowerment
Participation often includes enhanced health monitoring, which can give you a deeper understanding of your condition. This added knowledge can empower you to take control of your health with greater confidence and clarity.
Work with Leading Specialists
Our trials are conducted by experienced medical professionals and research teams dedicated to the highest standards of care. You’ll be in the hands of experts who are passionate about advancing medicine and supporting your journey.
Please Note:
Benefits may vary by study and are only available to individuals who meet eligibility criteria after completing the screening process. All services and compensations are subject to the specific terms of each clinical trial.
Current Clinical Trails
STABILIZE-CKD
Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants with CKD and Hyperkalemia or at Risk of Hyperkalemia
Status: Enrolling
Type of Study: A Phase 3, International, Randomized, Double-Blind,
Placebo Controlled Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Patients with CKD and Hyperkalemia or at Risk of Hyperkalemia
Study Length: 28 months
Target Age/Sex: Over 18 years, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://clinicaltrials.gov/ct2/show/NCT05056727
Description:
This is a Phase 3, international, randomized withdrawal, double-blind, parallel-group, placebo-controlled study, to evaluate the effect of SZC as adjunct to RAASi therapy (lisinopril or valsartan) in slowing CKD progression in participants with CKD and hyperkalemia or at risk of hyperkalemia.
Specifically, the study will include participants with hyperkalemia (S-K > 5.0 to ≤ 6.5 mmol/L by central laboratory) who are on adequate or limited RAASi therapy due to hyperkalemia, and participants with normokalaemia (S-K ≥ 3.5 to ≤ 5.0 mmol/L by central laboratory) who are on limited RAASi therapy due to high risk of hyperkalemia. High risk of hyperkalemia is defined as (1) participants with a previous medical history or record of hyperkalemia within the prior 24 months who are on limited RAASi therapy despite indication in CKD; (2) participants in whom RAASi therapy is indicated in CKD but are on limited RAASi therapy and have S-K ≥ 4.7 to ≤ 5.0 mmol/L; and (3) participants in whom RAASi therapy has been discontinued or reduced to suboptimal doses because of hyperkalemia.
Status: Enrolling
Type of Study: A Phase 3, Open-Label Study of Once Daily LY3502970
Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes
and Obesity or Overweight at Increased Cardiovascular Risk.
Study Length: 104 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://classic.clinicaltrials.gov/ct2/show/NCT05803421
Description:
ACHIEVE-4 is a clinical research study to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
QWINT-3
The QWINT-3 Study is testing an investigational basal insulin taken once weekly compared with basal insulin that is taken daily.
Status: Enrollment Completed
Type of Study: A Phase 2, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 2 Diabetes Mellitus Previously Treated With Basal Insulin
Study Length: 86 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://classic.clinicaltrials.gov/ct2/show/NCT03736785
Description:
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes that have already been treated with basal insulin.
ACHIEVE-1
Effect of LY3502970 Compared with Placebo in Participants with Type 2 Diabetes Inadequately Controlled with Diet and Exercise Alone
Status: Enrolling
Type of Study: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 compared with Placebo in Adult Participants with Type 2 Diabetes and inadequate Glycemic Control with Diet and Exercise Alone.
Study Length: 42 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Link: https://classic.clinicaltrials.gov/ct2/show/NCT03736785
Description:
The reason for this study is to compare the effects of LY3502970 and placebo on body weight and overall safety profile.
Upcoming
SYNCHRONIZE™-1
Efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes.
Status: Upcoming
Type of Study: A Phase III, randomized, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity without type 2 diabetes.
Study Length: 76 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Description:
This trial aims to provide evidence of the efficacy, safety, and tolerability of BI 456906 4.8 mg and 6.0 mg once weekly as an adjunct to a reduced-calorie diet and increased physical activity in comparison to placebo to BI 456906 in participants with obesity (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight-related co-morbidities but without T2DM.
SYNCHRONIZE™-2
A study to test whether BI 456906 helps people living with overweight or obesity who also have diabetes to lose weight.
Status: Upcoming
Type of Study: A Phase 3, randomized, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus.
Study Length: 76 weeks
Target Age/Sex: 18 Years and older, Male and Female
Benefits:
Participants will receive at no cost: study medication and study related supplies, study related lab work and study related exams.
Description:
The trial will compare BI 456906 3.6 mg with placebo, and BI 456906 6.0 mg with placebo as an adjunct to a reduced-calorie
diet and increased physical activity in trial participants with a BMI ≥27 kg/m2 and T2DM in terms of efficacy and safety.
Over 40 Previous Studies
SURMOUNT-2
Efficacy and Safety of Tirzepatide Once Weekly versus Placebo in Participants with Type 2 Diabetes Who Have Obesity or Are Overweight with Weight-Related Comorbidities
CSL346_2001
A Phase 2a, Double-blind, Randomized, Placebo-controlled, Proof of Concept Study of Vascular Endothelial Growth Factor (VEGF)-B Blockade with the Monoclonal Antibody CSL346 in Subjects with Diabetic Kidney Disease.
ANJ900D3501